These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30855104)

  • 1. Iron Chelation for Iron Overload in Thalassemia.
    Crisponi G; Nurchi VM; Lachowicz JI
    Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
    Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemical features of in use and in progress chelators for iron overload.
    Nurchi VM; Crisponi G; Lachowicz JI; Medici S; Peana M; Zoroddu MA
    J Trace Elem Med Biol; 2016 Dec; 38():10-18. PubMed ID: 27365273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron Chelation Therapy as a Modality of Management.
    Aydinok Y
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Management of Patients With Thalassemia Syndromes.
    Martin M; Haines D
    Clin J Oncol Nurs; 2016 Jun; 20(3):310-7. PubMed ID: 27206298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB; Shah FT
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload: The achilles heel of β-thalassemia.
    Vlachaki E; Venou TM
    Transfus Clin Biol; 2024 Aug; 31(3):167-173. PubMed ID: 38849068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 18th ICOC Proceedings in Athens, Greece: New breakthrough in thalassemia leading to the complete treatment of iron overload and to hundreds of patients achieving and maintaining normal body iron stores. Ethical questions on chelation therapy.
    Kontoghiorghes GJ
    Hemoglobin; 2010 Jun; 34(3):199-203. PubMed ID: 20524809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New developments in iron chelators.
    Cunningham MJ; Nathan DG
    Curr Opin Hematol; 2005 Mar; 12(2):129-34. PubMed ID: 15725903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalassemia.
    Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
    Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating iron overload in patients with non-transfusion-dependent thalassemia.
    Taher AT; Viprakasit V; Musallam KM; Cappellini MD
    Am J Hematol; 2013 May; 88(5):409-15. PubMed ID: 23475638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron overload in thalassemia: different organs at different rates.
    Taher AT; Saliba AN
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and treatment of transfusional iron overload in children.
    Ware HM; Kwiatkowski JL
    Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.